DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Phase 1

Completed

Conditions: Metastatic Triple Negative Breast Cancer
Metastatic Colorectal Cancer

Interventions: Biological: Talimogene Laherparepvec
Biological: Atezolizumab

First Posted Date: 2017-08-22

Last Posted Date: 2024-05-14

Lead Sponsor: Amgen

Target Recruit Count: 36

Registration Number: NCT03256344

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia

and more 14 locations

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Early Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Emerfetamab

First Posted Date: 2017-07-21

Last Posted Date: 2023-09-01

Lead Sponsor: Amgen

Target Recruit Count: 46

Registration Number: NCT03224819

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 4 locations

AMG 529 First in Human Study

Phase 1

Completed

Conditions: Cardiovascular

Interventions: Drug: AMG 529
Drug: Placebo

First Posted Date: 2017-05-30

Last Posted Date: 2019-07-05

Lead Sponsor: Amgen

Target Recruit Count: 48

Registration Number: NCT03170193

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Phase 3

Completed

Conditions: Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With
Glucocorticoid-induced Osteoporosis

Interventions: Other: Placebo
Drug: Denosumab

First Posted Date: 2017-05-24

Last Posted Date: 2024-07-19

Lead Sponsor: Amgen

Target Recruit Count: 24

Registration Number: NCT03164928

Locations: 🇦🇺
Perth Childrens Hospital, Nedlands, Western Australia, Australia
🇷🇺
FSAI Scientific Center of Childrens Health of MoH of the RF, Moscow, Russian Federation
🇹🇷
Ankara Universitesi Tip Fakultesi, Ankara, Turkey

and more 35 locations

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Phase 3

Completed

Conditions: Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib
Drug: Daratumumab

First Posted Date: 2017-05-18

Last Posted Date: 2025-05-09

Lead Sponsor: Amgen

Target Recruit Count: 466

Registration Number: NCT03158688

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Baylor Charles A Sammons Cancer Center at Dallas, Dallas, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 110 locations

Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Rozibafusp Alfa

First Posted Date: 2017-05-16

Last Posted Date: 2024-05-14

Lead Sponsor: Amgen

Target Recruit Count: 34

Registration Number: NCT03156023

Locations: 🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

and more 1 locations

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Apremilast
Other: Placebo

First Posted Date: 2017-04-21

Last Posted Date: 2020-05-13

Lead Sponsor: Amgen

Target Recruit Count: 303

Registration Number: NCT03123471

Locations: 🇺🇸
Dermatologic Surgery Specialists, P.C., Macon, Georgia, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Renstar Medical Research, Ocala, Florida, United States

and more 41 locations

Observational Study of Blinatumomab

Completed

Conditions: Blincyto Use in Routine Clinical Practice

First Posted Date: 2017-04-18

Last Posted Date: 2025-04-04

Lead Sponsor: Amgen

Target Recruit Count: 279

Registration Number: NCT03117621

Locations: 🇵🇱
Szpital Specjalistyczny imienia Ludwika Rydygiera w Krakowie Sp zoo, Kraków, Poland
🇵🇹
Centro Hospitalar de Lisboa Central, EPE - Hospital de Santo Antonio dos Capuchos, Lisboa, Portugal
🇨🇭
Universitaetsspital Basel, Basel, Switzerland

and more 77 locations

Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions

Completed

Conditions: Arthritis, Psoriatic

First Posted Date: 2017-04-10

Last Posted Date: 2020-08-31

Lead Sponsor: Amgen

Target Recruit Count: 526

Registration Number: NCT03106051

Locations: 🇩🇪
Klinikum Stephansplatz, Hamburg, Germany
🇩🇪
Rheumatology at Struenseehaus, Hamburg-Altona, Hamburg, Germany

A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: apremilast

First Posted Date: 2017-03-31

Last Posted Date: 2020-04-29

Lead Sponsor: Amgen

Target Recruit Count: 106

Registration Number: NCT03096990

Locations: 🇧🇪
CHU St Pierre (César de Paepe), Bruxelles, Belgium
🇧🇪
CHU Brugmann, Bruxelles, Belgium
🇧🇪
Reumaclinic, Genk, Belgium

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy